RAPT Therapeutics (NASDAQ:RAPT) Announces Earnings Results

RAPT Therapeutics (NASDAQ:RAPT) released its earnings results on Thursday. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.69), Zacks reports.

RAPT Therapeutics Stock Up 0.9 %

Shares of RAPT stock opened at $1.13 on Friday. The business has a 50-day moving average price of $1.25 and a two-hundred day moving average price of $1.56. RAPT Therapeutics has a 12-month low of $0.79 and a 12-month high of $10.05. The firm has a market cap of $39.50 million, a P/E ratio of -0.41 and a beta of -0.31.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on RAPT. JPMorgan Chase & Co. downgraded RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th. Stifel Nicolaus reiterated a “hold” rating and issued a $2.00 price target (down from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. Wells Fargo & Company reduced their price target on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research report on Tuesday, November 12th. HC Wainwright upgraded RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 price target for the company in a research report on Thursday, December 26th. Finally, Piper Sandler lowered RAPT Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $8.00 to $2.00 in a research note on Monday, November 11th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $5.29.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.